Companies join forces to transform the methods used by biopharmaceutical companies to contact, recruit and retain clinical trial patients
ClinPhone and NCERx have joined forces to transform the methods used by biopharmaceutical companies to contact, recruit and retain clinical trial patients.
By integrating ClinPhone's advanced screening, reporting and monitoring systems with the large-scale NCERx healthcare network and informatics platform, the companies have developed a seamless method to accelerate the enrolment of patients into clinical trials via timely information delivery, recruitment and reporting systems.
The new programme addresses major bottlenecks in the patient recruitment process, particularly those related to candidate access, communication and follow up.
Advanced data mining techniques will allow sponsors early access to potential patient populations while the advanced messaging opportunities provided by the collaboration will accelerate recruitment and improve retention and compliance.
In the past, many of the major 'traditional' patient recruiting and advertising firms have turned to NCERx to augment their own campaigns.
Now however, sponsors will be able to access these services directly from ClinPhone.
This integration greatly extends the power and reach of ClinPhone's patient recruitment technology.
This latest offering is described as a perfect fit with the company's electronic trial management systems designed to accelerate drug development processes and speed new drugs to market.
ClinPhone can now access, screen, recruit, and randomise patients into studies rapidly, reliably and efficiently.
As a leading healthcare information publisher, NCERx owns a high-traffic network of more than 875 internet sites.
Of these, over 350 are dedicated to providing patients with information on a wide range of conditions and therapeutic classes.
With an annual reach of over 100 million consumers, professionals and patients, the inclusion of lifestyle and health data in the HIPAA-compliant clinical trial database offers biopharmaceutical companies unparalleled and previously unavailable access to a vital patient resource.
Neil Rotherham, ClinPhone's managing director, states: "Industry figures show that a typical clinical trial costs a sponsor between $40,000 and $80,000 a day.
"Therefore, anything that can help to compress study timelines will result in immediate and significant savings.
"Patient recruitment is a key factor in completing studies on time and on budget and is why we have formed this alliance with NCERx.
"Not only does NCERx have the largest pool of opted-in study candidates, but it also has created a real sense of community for these candidates by delivering meaningful, well-researched information to them on a regular basis.
"The combined strengths of our companies will help sponsors to rapidly recruit and retain these patients. "This deal builds on ClinPhone's reputation for providing practical solutions to clients that deliver real value".
"This agreement benefits patients who are keen to participate in clinical trials and Biopharmaceutical companies researching new therapies," said Colin Lucas-Mudd, CEO of NCERx.
"With the dramatic increase in new chemical entities entering the clinical phase, there is clearly a need for a new, holistic approach to recruitment, compliance and retention. "We chose ClinPhone to take on marketing our services for multiple reasons.
"The synergies and limited overlap of the NCERx and ClinPhone technologies, combined with cultural fit and ClinPhone's excellent reputation and market presence made this a very easy agreement to conclude."
